Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Abstract
Anti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer. Platinum chemotherapies induce T-cell proliferation and enhance tumor recognition. We assessed activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2021
- Source ID
- 10.1136/jitc-2021-003122
Entities
People
- Andrew L. Coveler
- Anna V. Tinker
- Barbara A. Goff
- Doreen M. Higgins
- Hania N Shakalia
- James Y Dai
- Jennifer S. Childs
- John B Liao
- Kathryn F Mcgonigle
- Katie M. Hitchcock-bernhardt
- Mary L. Disis
- Renata R. Urban
- Richard G Ancheta
- Ron E. Swensen
- Sasha E Stanton
- Tanya A Wahl
- William R. Gwin
Organizations
- MSD (United Kingdom)
- United States Department of Defense